French pharmaceutical company Sanofi-Aventis announced a 10-year agreement with Covance on Thursday under which the Princeton, N.J.-based contract research firm will provide it with drug development services. Sanofi-Aventis wi…
Endo Pharmaceuticals (ENDP) agreed to buy generics company Qualitest Pharmaceuticals for $1.2 billion cash.
Qualitest is the sixth-largest U.S. generics company as measured by prescriptions filled. Qualitest will add about $400 million to Endo’s annual revenue and 40 cents per share in annual adjusted earnings, Endo said in a statement.
“We believe that this transaction will…
Continue reading Endo to Acquire Generics Company Qualitest for $1.2 Billion
Endo to Acquire Generics Company Qualitest for $1.2 Billion originally appeared on DailyFinance on Tue, 28 Sep 2010 06:31:00.
Filed Under: Company News, Health Care, Retail
Here’s a stock that is the largest drugstore operator in China, but still has huge growth ahead of it. The company just got costs under control, and has a new CEO. Plus, the stock is traded on the NYSE and sports a hefty dividend. Yet few know about it.
Continue reading Under the Radar: China’s Biggest Drugstore Chain Looks Cheap
Under the Radar: China’s Biggest Drugstore Chain Looks Cheap originally appeared on DailyFinance on Sun, 26 Sep 2010 06:00:00.
Filed Under: Investing
Novartis (NVS) agreed to sell the U.S. rights to bladder medicine Enablex for $400 million.
Ireland-based Warner Chilcott will take over the marketing, sales and manufacturing of the drug in the United States, Novartis said in a statement. The deal is expected to close by the end of October.
Novartis may also receive “milestone payments” of as much as $20 million.
In 2005, Novartis…
Continue reading Novartis Sells U.S. Rights to Enablex for $400 Million
Novartis Sells U.S. Rights to Enablex for $400 Million originally appeared on DailyFinance on Fri, 24 Sep 2010 06:46:00.
Filed Under: Company News, Health Care, Novartis, Insurance, Retail
Looking for stocks that could move fast? Hilary Kramer, editor of GameChangerStocks.com, recommends taking a look at two lesser-known pharmaceuticals, Shire and Medco Health Systems, that she says will benefit greatly in the near term.
Continue reading Under the Radar: Two Ways to Profit from Growth in Pharmaceuticals
Under the Radar: Two Ways to Profit from Growth in Pharmaceuticals originally appeared on DailyFinance on Wed, 22 Sep 2010 15:30:00.
Filed Under: Investing, JP Morgan Chase, Johnson & Johnson, Pfizer, Merck